Apellis Pharmaceuticals Inc ROCE
Quel est le ROCE de Apellis Pharmaceuticals Inc?
Le ROCE de Apellis Pharmaceuticals Inc est -40.79%
Quelle est la définition de ROCE?
Le retour sur capital utilisé (ROCE) est un ratio financier qui mesure la rentabilité d'une entreprise et l'efficacité avec laquelle son capital est utilisé.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE des entreprises dans Health Care secteur sur NASDAQ par rapport à Apellis Pharmaceuticals Inc
Que fait Apellis Pharmaceuticals Inc?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Entreprises avec roce similaire à Apellis Pharmaceuticals Inc
- WISeKey International Ltd a ROCE de -41.00%
- WISeKey International AG a ROCE de -41.00%
- LiqTech International a ROCE de -40.94%
- LiqTech International Inc a ROCE de -40.94%
- NioCorp Developments a ROCE de -40.90%
- Temas Resources a ROCE de -40.85%
- Apellis Pharmaceuticals Inc a ROCE de -40.79%
- Oak Street Health a ROCE de -40.74%
- Adamas Pharmaceuticals Inc a ROCE de -40.72%
- Silver Wolf Exploration a ROCE de -40.67%
- Sherpa II a ROCE de -40.64%
- The Mandhana Retail Ventures a ROCE de -40.63%
- Aclaris Therapeutics Inc a ROCE de -40.61%